description of the lupus anticoagulant was in a patient with a bleeding tendency, it is now recognised that the presence of a lupus anticoagulant is sometimes paradoxically associated with a tendency to thrombosis.f5 An association between the lupus anticoagulant and pulmonary hypertension has been identified amongst patients with systemic lupus erythematosus (SLE). 6 We describe a patient with a lupus anticoagulant who developed pulmonary hypertension following recurrent episodes of deep venous thrombosis (DVT) and pulmonary thromboembolism despite prolonged anticoagulant therapy.
Case report
A 26-year-old male presented in April 1972 with a two-week history of fever, cough, and pleuritic chest pain, and signs of DVT The lupus anticoagulant and anticardiolipin levels, assayed by a new sensitive solid-phase radioimmunoassay, are strongly associated with venous and arterial thrombosis-'5 and pulmonary hypertension.6t The lupus anticoagulant also is associated with abortions."6 17 The paradoxical association between the lupus anticoagulant and thrombosis is incompletely explained but mat be related to reduced prostacyclin formation' or activity.t9 In previously reported cases recurrent thrombosis could be prevented by anticoagulant therapy, 3 xbut our patient had recurrent pulmonary emboli resulting in fatal pulmonary hypertension despite continuous warfarin therapy for all but three months after his initial presentation. Reduced fibrinolytic activity in the vessel wallst may contribute to the tendency for pulmonary thromboemboli to produce irreversible pulmonary hypertension in patients with a lupus anticoagulant. Therapy with low doses of streptokinase may be beneficial.
The lupus anticoagulant is rarely associated with bleeding symptoms, even during major surgical procedures't3 or in the presence of thrombocytopenia.5 When bleeding occurs it is usually attributable to another cause. 7 Our patient had no haemorrhagic complication despite prolonged oral anticoagulant therapy.
An association between the lupus anticoagulant and pulmonary hypertension has been described in patients with SLE. Suggested possible factors in the pathogenesis of pulmonary hypertension in these patients are vasospasm, arteritis, platelet dysfunction, and thromboembolism. 
